Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Nicholas Ryan(Tanjungpura University), Clara Saldarriaga(British Heart Foundation), Justin A. Ezekowitz(University of Alberta), Burkert Pieske(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Adrian F. Hernandez(Duke University), Piotr Ponikowski(Wroclaw Medical University), Alessia Urbinati(Marche Polytechnic University), Stefano Corda(Université Paris Cité), Javed Butler(Jackson Memorial Hospital), Eldrin F. Lewis(Brigham and Women's Hospital), Yogesh N.V. Reddy(Mayo Clinic), Ciaran J. McMullan(Harvard University), Joerg Koglin(Ludwig-Maximilians-Universität München), Maria Borentain(Bayer (United States)), Vanja Vlajnic(Bayer (United States)), Robert J. Mentz(Duke University), Irina Barash(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kevin J. Anstrom(University of North Carolina at Chapel Hill), P. Pinto Teixeira(Bayer (Germany)), James E. Udelson(Tufts Medical Center), Constance Hamlin, Cynthia M. Westerhout(Canadian VIGOUR Centre), Tracy Temple, Marc P. Bonaca(The Medical Center of Aurora), Paul W. Armstrong(University of Alberta), JoAnn Lindenfeld(Vanderbilt University Medical Center), Adriaan A. Voors(The Medical Center of Aurora), Mahesh J. Patel, Aiwen Xing(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher M. O’Connor(Inova Health System), Christopher M. O'Connor, Carolyn S.P. Lam(National University of Singapore), Davis Gates(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lothar Roessig(Bayer (Germany)), Lisa Soulard, Giuseppe Rosano(San Raffaele University of Rome)
Cited by 39
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k